Breaking News

Trevi Therapeutics Taps David Hastings as CFO

Hastings brings over 25 years of financial leadership in public life sciences and biopharmaceutical companies to Trevi.

Author Image

By: Charlie Sternberg

Associate Editor

Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company, has named David Hastings as Chief Financial Officer, effective January 6, 2026. “I am thrilled to welcome Dave to the leadership team as we enter an important chapter of growth at Trevi,” said Jennifer Good, President and CEO of Trevi Therapeutics. “His proven track record and experience as we transition into Phase 3 development and beyond will be critical as we continue to advance Haduvio for the treatment...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters